Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 17
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
8/1/1990
1.
Phase III Efficacy and Safety Trial of Toremifene vs Tamoxifen in Postmenopausal/Perimenopausal Patients with Metastatic Breast Cancer (Summary Last Modified 08/90)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
peri/postmenopausal
GUMC-9989
NCI-V89-0180
Last Modified:
11/1/1991
2.
Phase III Efficacy and Safety Trial of Toremifene vs Tamoxifen in Postmenopausal/Perimenopausal Patients with Metastatic Breast Cancer (Summary Last Modified 11/91)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
post/perimenopausal
AECM-8805150
NCI-V89-0202
Last Modified:
1/1/1990
3.
Phase III Efficacy and Safety Trial of Toremifene vs Tamoxifen in Postmenopausal/Perimenopausal Patients with Metastatic Breast Cancer (Summary Last Modified 01/90)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
post/perimenopausal
TCSC-092006-999
NCI-V89-0043
Last Modified:
5/1/1990
4.
Phase III Trial of the Efficacy and Safety of Toremifene vs Tamoxifen in Postmenopausal and Perimenopausal Patients with Metastatic Breast Cancer (Summary Last Modified 05/90)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
postmenopausal
YALE-HIC-5026
NCI-V89-0229
Last Modified:
5/12/2008
5.
Phase III Randomized Study of Adjuvant Endocrine Therapy (Tamoxifen vs Toremifene) with vs without Anthracycline/Cyclophosphamide (AC) in Peri- and Postmenopausal Women with Node-Positive Breast Cancer, with Chemotherapy Started Either Concurrently with or Prior to Endocrine Therapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
under 71
IBCSG-12-93
EU-93015, NCI-F93-0010, NCT00002529
Last Modified:
5/12/2008
6.
Phase III Randomized Study of Adjuvant Anthracycline/Cyclophosphamide and Cyclophosphamide/Methotrexate/Fluorouracil with vs without a 16-Week Treatment-Free Interval Between Regimens and with Subsequent Tamoxifen vs Toremifene in Peri- and Postmenopausal Women with Node-Positive Breast Cancer Unsuitable for Endocrine Therapy Alone
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
under 71
IBCSG-14-93
EU-93017, NCI-F93-0012
7.
Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 and over
Pharmaceutical / Industry
Biomed 777-CLP-29
NCT00044291
8.
Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Prevention
Closed
30 and over
Pharmaceutical / Industry
G300104
NCT00106691
9.
Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Closed
50 and over
Pharmaceutical / Industry
G300203
NCT00129142
Last Modified:
7/1/2001
10.
Phase II Study of Toremifene in Patients With Desmoid Tumors (Summary Last Modified 07/2001)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
16 and over
Other
LGH-1011
NCI-V91-0211, NCT00002595
Select All on One Page
1
2
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute